@article{f307b69c2a7547f7b65e4864b8e6d847,
title = "The international association for the study of lung cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung cancer: Status in 2016",
abstract = "Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent {"}actionable{"} alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKIs) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of the third-generation EGFR TKI osimertinib, available systemic and local treatment options have expanded, requiring new clinical algorithms that take into account individual patient molecular and clinical profiles. In this International Association for the Study of Lung Cancer commissioned consensus statement, key pathologic, diagnostic, and therapeutic considerations, such as optimal choice of EGFR TKI and management of brain metastasis, are discussed. In addition, recommendations are made for clinical guidelines and research priorities, such as the role of repeat biopsies and use of circulating free DNA for molecular studies. With the rapid pace of progress in treating EGFR-mutant NSCLC, this statement provides a state-of-theart review of the contemporary issues in managing this unique subgroup of patients.",
keywords = "Brain metastases, EGFR mutation, Non-small cell lung cancer, Resistance, Therapy, Tyrosine kinase inhibitor",
author = "Tan, {Daniel S.W.} and Yom, {Sue S.} and Tsao, {Ming S.} and Pass, {Harvey I.} and Karen Kelly and Nir Peled and Yung, {Rex C.} and Wistuba, {Ignacio I.} and Yasushi Yatabe and Michael Unger and Mack, {Philip C.} and Wynes, {Murry W.} and Tetsuya Mitsudomi and Walter Weder and David Yankelevitz and Herbst, {Roy S.} and Gandara, {David R.} and Carbone, {David P.} and Bunn, {Paul A.} and Mok, {Tony S.K.} and Hirsch, {Fred R.}",
note = "Funding Information: Disclosure: Dr. Tan reports personal fees from Celgene, Eisai, and Pfizer; grants and personal fees from Novartis; and grants from GlaxoSmithKline, AstraZeneca, and Bayer outside the submitted work. Dr. Yom reports grants from the National Comprehensive Cancer Network Foundation, Genentech, and Clinigen; royalties from UpToDate, and honoraria from the American Society of Radiation Oncology outside the submitted work. Dr. Tsao reports grants and personal fees from AstraZeneca Canada during the conduct of the study; grants and personal fees from Pfizer Canada; and personal fees from Bristol-Myers Squib, Merck, and Hoffmann LaRoche outside the submitted work. Dr. Kelly reports receiving the following outside the submitted work: personal fees and nonfinancial support from Boehringer Ingelheim; personal fees from Clovis; personal fees and compensation for serving on advisory boards and for research of clinical trials from Lilly; grants, personal fees, nonfinancial support and compensation from Genentech for attending advisory board meetings, travel, conducting research of clinical trials, and serving on a data monitoring committee; personal fees from Transgene; personal fees, nonfinancial support, and compensation from Celgene for attending advisory board meetings, travel, and conducting research of clinical trials; personal fees and compensation from Synta for attending advisory board meetings and conducting research of clinical trials; personal fees, nonfinancial support, and compensation from AstraZeneca for attending advisory board meetings, travel, conducting research of clinical trials, and serving on a data monitoring committee; personal fees and nonfinancial support from Ariad; compensation for conducting research of clinical trials from Millennium, Novartis, EMD Serono, AbbVie, and Gilead; and author royalties UpToDate. Dr. Wistuba reports grants and personal fees from Genentech/Roche, personal fees from AstraZeneca and Clovis during the conduct of the study, and he also reports personal fees from Glaxo Smith Kline, Celgene, Bristol-Myers Squibb, Synta, Boehringer Ingelheim, Medscape, Asuragen, Ariad, and HTG Molecular, as well as grants from HTG Molecular and Oncoplex outside the submitted work. Dr. Yatabe reports personal fees from AstraZeneca, Novartis, and Merck, Sharp, and Dohme, as well as from Pfizer, Chugai Pharma, Taiho, and Roche outside the submitted work. Dr. Mack reports personal fees from AstraZeneca, Novartis, Guardant Health, MolecularMD, and Apton Biosystems and grants from Boehringer Ingelheim outside the submitted work. Tetsuya Mitsudomi reports personal fees from AstraZeneca and grants and personal fees from Chugai and Boehringer Ingelheim during the conduct of the study; he also reports grants and personal fees from Pfizer, Ono, and Taiho and personal fees from Merck, Sharp, and Dohme and from Bristol-Myers Squibb and Eli Lilly outside the submitted work. Dr. Herbst reports personal fees from Genentech, Merck, Boehringer Ingelheim, Pfizer, and AstraZeneca during the conduct of the study. Dr. Gandara reports grants and other from Genentech, AstraZeneca, and Boehringer-Ingelheim outside the submitted work. Dr. Carbone reports personal fees from Ariad, AstraZeneca, Bayer HealthCare, Biothera, Boehringer Ingelheim, Clovis Oncology, Genentech of Roche, Guardant Health, Inivata, Janssen Diagnostics, Merck, Novartis, Peregrine Pharmaceuticals, Synta Pharmaceuticals, and Teva Pharmaceuticals and grants and personal fees from Bristol-Myers Squib during the conduct of the study. Dr. Bunn Jr. reports personal fees from Astra Zeneca, Genentech, and Clovis during the conduct of the study. Dr. Mok reports personal fees from the following companies outside the submitted work: AstraZeneca; Roche/Genentech; Lilly; Merck Serono; ACEA Biosciences; Bristol-Myers Squib; AVEO and Biodesix; Pfizer; Boehringer Ingelheim; Novartis Pharmaceuticals; GlaxoSmithKline; Clovis Oncology; Amgen; Janssen; BioMarin Pharmaceuticals; SFJ Pharmaceuticals; Merck, Sharp, and Dohme; Vertex Pharmaceuticals; Prime Oncology; Sanomics Ltd.; geneDecode; and Oncogenex. Dr. Hirsch reports grants from AstraZeneca during the conduct of the study and compensation outside the submitted work from AstraZeneca, Genentech/Roche, Bristol-Myers Squib, Lilly, Pfizer, and Boehringer-Ingelheim for participating in advisory board meetings; in addition, he is chief executive officer of the International Association for the Study of Lung Cancer. State of the Art: Concise Review Publisher Copyright: {\textcopyright} 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.",
year = "2016",
doi = "10.1016/j.jtho.2016.05.008",
language = "English (US)",
volume = "11",
pages = "946--963",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "7",
}